Hayley Wooding1, Jing Yan2, Ling Yuan2, Te-Yu Chyou3, Shanbao Gao2, Iain Ward1, Patries M Herst4. 1. 1 Canterbury Regional Cancer and Haematology Service, Christchurch Hospital , Christchurch , New Zealand. 2. 2 Comprehensive Cancer Centre, Drum Tower Hospital/Clinical Cancer Institute of Nanjing University , Nanjing , PR China. 3. 3 Department of Radiation Oncology, Southern Blood and Cancer Centre, Dunedin Hospital , Dunedin , New Zealand. 4. 4 Department of Radiation Therapy, University of Otago , Wellington , New Zealand.
Abstract
OBJECTIVE:Mepitel Film significantly decreases acute radiation-induced skin reactions in breast cancer patients. Here we investigated the feasibility of using Mepitel Film in head and neck cancer patients (ACTRN12614000932662). METHODS: Out of a total of 36 head and neck cancer patients from New Zealand (NZ) (n = 24) and China (n = 12) recruited between June 2015 and December 2016, 33 patients complied with protocol. Of these, 11 NZ patients followed a management protocol; 11 NZ patients and 11 Chinese patients followed a prophylactic protocol. An area of the neck receiving a homogenous radiation dose of > 35 Gy was divided into two equal halves; one half was randomized to Film and the other to either Sorbolene cream (NZ) or Biafine cream (China). Skin reaction severity was measured by Radiation Induced Skin Reaction Assessment Scale and expanded Radiation Therapy Oncology Group toxicity criteria. Skin dose was measured by thermoluminescent dosimeters or gafchromic film. RESULTS: Film decreased overall skin reaction severity (combined Radiation Induced Skin Reaction Assessment Scale score) by 29% and moist desquamation rates by 37% in the Chinese cohort and by 27 and 28%, respectively in the NZ cohort. Mepitel Film did not affect head movements but did not adhere well to the skin, particularly in males with heavy beard stubble, and caused itchiness, particularly in Chinese patients. CONCLUSION:Mepitel Film reduced acute radiation-induced skin reactions in our head and neck cancer patients, particularly in patients without heavy stubble. Advances in knowledge: This is the first study to confirm the feasibility of using Mepitel Film in head and neck cancer patients.
RCT Entities:
OBJECTIVE: Mepitel Film significantly decreases acute radiation-induced skin reactions in breast cancerpatients. Here we investigated the feasibility of using Mepitel Film in head and neck cancerpatients (ACTRN12614000932662). METHODS: Out of a total of 36 head and neck cancerpatients from New Zealand (NZ) (n = 24) and China (n = 12) recruited between June 2015 and December 2016, 33 patients complied with protocol. Of these, 11 NZ patients followed a management protocol; 11 NZ patients and 11 Chinese patients followed a prophylactic protocol. An area of the neck receiving a homogenous radiation dose of > 35 Gy was divided into two equal halves; one half was randomized to Film and the other to either Sorbolene cream (NZ) or Biafine cream (China). Skin reaction severity was measured by Radiation Induced Skin Reaction Assessment Scale and expanded Radiation Therapy Oncology Group toxicity criteria. Skin dose was measured by thermoluminescent dosimeters or gafchromic film. RESULTS: Film decreased overall skin reaction severity (combined Radiation Induced Skin Reaction Assessment Scale score) by 29% and moist desquamation rates by 37% in the Chinese cohort and by 27 and 28%, respectively in the NZ cohort. Mepitel Film did not affect head movements but did not adhere well to the skin, particularly in males with heavy beard stubble, and caused itchiness, particularly in Chinese patients. CONCLUSION: Mepitel Film reduced acute radiation-induced skin reactions in our head and neck cancerpatients, particularly in patients without heavy stubble. Advances in knowledge: This is the first study to confirm the feasibility of using Mepitel Film in head and neck cancerpatients.
Authors: Amanda Bolderston; Nancy S Lloyd; Rebecca K S Wong; Lori Holden; Linda Robb-Blenderman Journal: Support Care Cancer Date: 2006-06-07 Impact factor: 3.603
Authors: Elvio G Russi; Francesco Moretto; Monica Rampino; Marco Benasso; Almalina Bacigalupo; Vitaliana De Sanctis; Gianmauro Numico; Paolo Bossi; Michela Buglione; Antonino Lombardo; Mario Airoldi; Marco C Merlano; Lisa Licitra; Nerina Denaro; Stefano Pergolizzi; Carmine Pinto; Renè-Jean Bensadoun; Giampiero Girolomoni; Johannes A Langendijk Journal: Crit Rev Oncol Hematol Date: 2015-07-02 Impact factor: 6.312
Authors: Patries M Herst; Noelle C Bennett; Annie E Sutherland; Ruth I Peszynski; Dean B Paterson; Marieke L Jasperse Journal: Radiother Oncol Date: 2014-01-30 Impact factor: 6.280
Authors: N Salvo; E Barnes; J van Draanen; E Stacey; G Mitera; D Breen; A Giotis; G Czarnota; J Pang; C De Angelis Journal: Curr Oncol Date: 2010-08 Impact factor: 3.677
Authors: Elaine Barros Ferreira; Christiane Inocêncio Vasques; Rafael Gadia; Raymond Javan Chan; Eliete Neves Silva Guerra; Luis André Mezzomo; Graziela De Luca Canto; Paula Elaine Diniz Dos Reis Journal: Support Care Cancer Date: 2016-12-12 Impact factor: 3.603
Authors: Leonard Christopher Schmeel; David Koch; Frederic Carsten Schmeel; Bettina Bücheler; Christina Leitzen; Birgit Mahlmann; Dorothea Kunze; Martina Heimann; Dilini Brüser; Alina-Valik Abramian; Felix Schoroth; Thomas Müdder; Fred Röhner; Stephan Garbe; Brigitta Gertrud Baumert; Hans Heinz Schild; Timo Martin Wilhelm-Buchstab Journal: Polymers (Basel) Date: 2019-12-16 Impact factor: 4.329